Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 11.56%
As of Tuesday, October 20, Larimar Therapeutics, Inc.’s LRMR share price has surged by 11.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Commentary & Analysis
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 14.62%
As of Tuesday, October 20, Larimar Therapeutics, Inc.’s LRMR share price has surged by 14.62%, which has investors questioning if this is right time to sell.Omar Beirat
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.58%
As of Tuesday, October 13, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.74%
As of Monday, October 05, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 8.54%
As of Thursday, September 24, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 8.54%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $265.1 | $232.8 | 31% |
|
| Shares Out (Mil) | 104.4 | 53.4 | 63% |
|
| Institutional Ownership | 97.7% | 92.9% | 75% |
|
| Float (Mil) | 57.9 | 41.2 | 50% |
|
| Beta | 0.75 | 0.96 | 44% |
|
| Avg Daily Volume (000s) | 1,866 | 490 | 80% |
|
| Price Change (52-week) |
(41.5%) | 48.2% | 24% |
|
| Growth | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (31.3%) | (10.1%) | 13% |
|
| EPS (5yr) | 8.7% | 15.8% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.0%) | (15.7%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 8 | |
| Current EPS | ($0.349) | ($1.351) | ($1.060) | |
| Month Ago EPS | ($0.349) | ($1.351) | ($1.060) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.421) | ($1.607) | ($1.180) | |
| Year/Year Chg | 11.1% | (40.5%) | (82.8%) | |
| Financials | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($173) | ($44) | 8% |
|
| EPS (TTM) | ($1.926) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($156) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $72 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $249 | $174 | 28% |
|
| Valuation | LRMR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.08 | 2.22 | 55% |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (109.5%) | (47.3%) | 5% |
|
| ROE | (139.6%) | (53.3%) | 7% |
|
| Liabilities to Assets | 22.9% | 29.4% | 15% |
|
| F-Score | 1 | 2 | 1% |
|
Larimar Therapeutics, Inc. did not pass any screens on 10/28/2026.
